Benefits of CyberKnife® Lung Radiosurgery Treatments Emphasized During Europe's Largest Congress in Radiation Oncology

Conference Presentations Highlight CyberKnife Motion Management Capabilities in Treatment of Lung Cancer

News provided by

Sep 17, 2010, 02:20 ET

SUNNYVALE, Calif., Sept. 17 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that for the first time in Europe the company showcased its latest offering, the CyberKnife VSI System, at ESTRO 29; the Annual Congress of the European Society for Therapeutic Radiology and Oncology in Barcelona, Spain. Also featured at this meeting were multiple presentations demonstrating this system's best-in-class motion management capabilities for lung cancer care.

During a well-attended symposium on motion management in lung radiosurgery chaired by Pr. Volker Budach, M.D., Ph.D., Charite – Universitatsmedizin, Berlin, physics and clinical findings were presented by representatives from two CyberKnife sites: Erasmus MC - Daniel den Hoed Cancer Centre in Rotterdam, Netherlands and Centre Antoine Lacassagne in Nice, France. Clinical research presented during the symposium demonstrated the benefits of CyberKnife radiosurgery in the treatment of primary early stage and metastatic lung cancer, including excellent disease control and preservation of quality of life. Enabling these outcomes are the CyberKnife System's unique motion management capabilities including the Synchrony® Respiratory Tracking System, which enables real-time tracking and correction for tumors that move with respiration.

"The Synchrony System is unique in its ability to correct for changes in a patient's pattern of breathing in real-time," said Dr. Joost Nuyttens, M.D., Ph.D., Erasmus MC – Daniel den Hoed Cancer Center, Rotterdam. "This allows us to significantly reduce delivery margins while eliminating the need for abdominal compression or breath-holding techniques."

In addition, two CyberKnife users were recognized for outstanding research. The ACCURAY-ESTRO Award, which for the last several years has recognized radiotherapy professionals for original research in the field of high precision radiotherapy, was awarded to Dr. Joost Nuyttens (Rotterdam), for his lecture entitled "Outcome of Four-dimensional Stereotactic Radiotherapy for centrally located Lung Tumors". Within the National Young Scientist Session, the first prize was won by Jean-Emmanuel Bibault, Resident, Centre Oscar Lambret, Lille for his oral poster reporting on outcomes obtained using the fiducial-free Xsight® Lung Tracking System titled, "Early efficacy and toxicity evaluation of CyberKnife Xsight Lung."

"Both of these awards highlight industry-leading approaches to non-invasive lung cancer treatment using CyberKnife radiosurgery," said Vittorio Puppo, General Manager, Accuray EIMEA (Europe, India, Middle East, Asia). "We congratulate our productive and dedicated users on this fine honor and thank them for their important research contributions."

More than 20 posters and oral presentations during this year's ESTRO meeting highlighted the continued expansion of extracranial radiosurgery applications with the CyberKnife System, including presentations on lung, liver, prostate, spine, pancreas, and head and neck cancer.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 95,000 patients worldwide and currently more than 206 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical efficacy, clinical benefits, clinical acceptance, clinical publications, and clinical results are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2010 fiscal year which has been filed with the Securities and Exchange Commission on August, 31, 2010. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated